Answers are grounded in this paper and cite their sources.
Clinical practice evaluates satralizumab's impact on pain, medication use, and glucocorticoid reduction in NMOSD, suggesting benefits.
To evaluate changes in pain severity, number and types of concomitant medications, and glucocorticoid (GC) tapering following satralizumab treatment in patients with neuromyelitis optica spectrum disorder (NMOSD) in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Ikeguchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: